Winthrop Advisory Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-6,590
Closed -$303K 125
2022
Q1
$303K Buy
6,590
+2,922
+80% +$139K 0.06% 100
2021
Q4
$225K Buy
3,668
+2
+0.1% +$138 0.05% 128
2021
Q3
$274K Sell
3,666
-17
-0.5% -$1.43K 0.06% 107
2021
Q2
$340K Sell
3,683
-33
-0.9% -$2.81K 0.08% 90
2021
Q1
$330K Buy
3,716
+253
+7% +$25.1K 0.08% 89
2020
Q4
$323K Buy
+3,463
New +$276K 0.08% 88

Other funds holding ARKG

Winthrop Advisory Group's ARKG Position: Q2 2022 in Review

Winthrop Advisory Group sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 6,590 shares — an estimated $303K sold.

Winthrop Advisory Group first reported a position in ARKG in Q4 2020 and held it in 6 quarters. The position peaked at $340K in Q2 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Winthrop Advisory Group reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Winthrop Advisory Group sold 6,590 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $303K.
  • Winthrop Advisory Group first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 6 quarters.
  • Winthrop Advisory Group's ARK Genomic Revolution ETF position peaked at $340K in Q2 2021.
  • 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Winthrop Advisory Group's 13F filing for Q2 2022, filed 21 Jul 2022.